BAP Pharma Announces Grand Opening Ceremony for New US Headquarters in Somerset, NJ
BAP Pharma Announces Grand Opening Ceremony for New US Headquarters in Somerset, NJ
BAP Pharma announced today that the Grand Opening Ceremony of its new US headquarters will be held on Wednesday, 24th of April 2024.
BAP Pharma will welcome guests and dignitaries to the Grand Opening Ceremony of its new headquarters on Randolph Road with a formal ribbon cutting ceremony, speeches, and exclusive tours of the new facility.
First setting up US operations in Landing, New Jersey in 2016, BAP Pharma experienced extraordinary success and growth fueled by new customer acquisition, diversification, and expansion into new markets. This resulted in the formation of two new divisions to complement the original Comparator Sourcing business - Clinical Secondary Packaging and Labelling and Medicines Access – and necessitated the move to a much larger facility with a broader range of capabilities.
BAB Pharma’s new US headquarters are in a modern, state-of-the-art 28,000 sq. ft. facility and are fully licensed by the New Jersey State Department of Health. Some of its capabilities include a 24-hour temperature-controlled and monitored warehouse with ambient (+15°C to +25°C), cold (+2°C to +8°C), and freezer (-20°C) storage facilities.
Additionally, BAP Pharma’s US facility can provide in-house label design and print, temperature-controlled clinical secondary packaging, and just-in-time/on-demand labelling.
Dr. Bashir Parkar, Founder and Managing Director of BAP Pharma, established the company in 2011 to provide the high-quality supply of comparator drugs for clinical trials to help overcome the common barriers to treatment for patients. By providing a total global solution as a top-tier service provider, BAP Pharma delivers medicines to patients at the right time, at the right place, and at the right temperature.
Dr. Parkar stated, “We are excited to have invested into a new modern facility in New Jersey, which will enable further development and growth in our key business area of Comparator Sourcing, as well as now offering Clinical Secondary Packaging & Labelling and Medicines Access services. The facility and location proved a perfect fit for our company. Its proximity to a significant number of global pharmaceutical and biotechnology companies, including our current clients, made it particularly attractive. New Jersey’s excellent transportation network also enhances our ability to deliver products quickly and efficiently throughout the region and around the world.”
BAP Pharma is a UK based, award-winning, global leader in clinical trials supply, specializing in comparator sourcing, clinical secondary packaging/labelling, and medicines access.
BAP Pharma has established a global reputation within the industry as a reliable partner by building strong connections with clients to gain their loyalty, and it now counts some of the world’s largest names in pharmaceutical manufacturing as their clients.
For more information on the Grand Opening Ceremony, please contact us at enquiries@bappharma.com
BAP Pharma Ltd.
Ken Dobbie
+44 (0)1753 924 768
Ken.Dobbie@bappharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409072101/en/
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track